In addition, mutations in IDH1 and IDH2 have been linked to AML.199 Using selective IDH inhibitors, such as Enasidenib (AG-221, CC-90007) in patients with mutated IDH, ameliorates production of the oncometabolite (D)-2 hydroxyglutarate (D-2-HG) and associated pro-tumor effects, thereby providing a novel therapeutic approach in cancers such as AML.200,201 ACLY is the transferase that catalyzes the conversion of citrate and coenzyme A to acetyl-CoA during fatty acid metabolism. Here, IDH2 is linked to cancer.